MedDocIQ — Physician-Led Clinical Trial Documentation for Uzbekistan and Central Asia
Physician-Led | US-Based | Uzbekistan-first | Central Asia expansion
MedDocIQ provides physician-led Protocol Feasibility Review and ICF Cultural Localization + Clinical Validation (EN to RU/UZ) for clinical trials in Uzbekistan and Central Asia. We deliver audit-friendly documentation with tracked changes, Study Glossary, Clinical Intent Verification Note (CIVN), and Localization Validation Certificate.
Our Services
Tier 1: Trial Startup Bundle — Feasibility to ICF Cultural Localization
The complete physician-led startup package: feasibility de-risk + ICF localization in one coordinated workflow. Includes Protocol Feasibility and Readiness Memo, SoA to ICF Alignment Map, Study Glossary + Term Decision Register, tracked-changes + clean copy (RU and/or UZ), and Clinical Intent Verification Note (CIVN). Pricing: Custom.
Tier 2: Protocol Feasibility Only (Uzbekistan lens)
Physician-led review of your English draft protocol through a Uzbekistan-specific lens, identifying execution risks, ethics committee friction points, and patient-facing clarity gaps before a single word is localized. Includes risk memo, ICF-relevant risk flags, SoA to ICF Alignment Notes, Study Glossary starter, and optional sponsor handoff call. Pricing: Custom.
Tier 3: ICF Cultural Localization + Clinical Validation (RU/UZ) — $1,200
Native Uzbek and Russian linguists localize your ICF for patient-facing clarity, followed by physician clinical review to confirm intent and terminology consistency. Turnaround: 7 to 10 business days. Includes tracked-changes + clean copy, physician Clinical QC (GCP-aware), glossary alignment, and CIVN.
Tier 4: Second-Pass Clinical Validation (Existing RU/UZ)
Already have a RU/UZ ICF from another vendor? Our physician team reviews clinical intent, terminology consistency, and patient-facing clarity, returning a tracked correction set prepared to support ethics re-submission. Pricing: Custom.
Why MedDocIQ?
-
Physician-Led Medical Accuracy Review:
Medical meaning reviewed by a physician to protect clinical intent and reduce avoidable rework during ethics/IRB review.
-
GCP-Aware Quality Control:
Structured QA checklist supports consistency, completeness, and terminology alignment appropriate for clinical trial documentation.
-
Native Russian + Uzbek Linguists:
Native linguists with English-source ICF focus.
-
Glossary and Terminology Consistency:
Master glossary ensures consistent medical language across all ICF sections and versions.
Why Central Asia for Clinical Trials?
Central Asia represents a rapidly growing frontier for clinical trials. Uzbekistan has a population exceeding 36 million and the largest pharmaceutical market in Central Asia at over $2 billion, with 36%+ year-over-year growth. The region offers large treatment-naive patient populations, minimal trial competition, cost-effectiveness, and a modernizing regulatory environment.
Our Process
MedDocIQ follows a structured, physician-led methodology: (1) Protocol Feasibility Review through an Uzbekistan-specific lens, (2) ICF Cultural Localization by native RU/UZ linguists, (3) Physician Clinical Validation for intent and terminology, (4) Audit-friendly delivery with full artifact package.
Coming Soon
Central Asia Expansion: Kazakhstan, Kyrgyzstan, and Tajikistan. Additional patient-facing document localization including recruitment materials, patient brochures, and participant diaries/questionnaires.
Navigate
Contact
Email:
contact@meddociq.com
LinkedIn:
linkedin.com/company/meddociq